Chemotherapy resistance in cancer patients may be due to serum blocking factors, which can be deminished or eliminated by large volume plasma exchange (PE). This procedure was performed with the IBM blood cell separator in 69 patients resistant to chemotherapy. Immediately after PE the chemotherapy was given but it failed to produce remission. The combined treatment was reinstituted, if clinical evaluation revealed partial remission, minor response or no change. 37 out of 69 patients (53.6%) responded again, 32 (46.4%) did not. Response duration ranged from 2 to 45 weeks. Best clinical results were obtained in patients with colorectal cancer, 15 out of 23 showed improvement between 4 to 45 weeks. Serum blocking activity was measured using a modified mixed lymphocyte culture assay (MLC). There was a 80% positive correlation between clinical course of patients and MLC levels, if basic activity before the first PE was compared to MLC inhibition before the following PE's.
KamoI., FriedmanH.: Immunosuppression and the role of suppressive factors in cancer.Adv. Cancer. Res.25: 271, 1977.
4.
LovettE.J., VeraniJ.: Immunosuppression induced in culture supernatants from tumor cell variant in proportional to the metastatic potential of the tumor clone. 6th Meeting of the European Association for Cancer Research, Budapest 1981, Abstract No. 33.
5.
PlesciaO.J., SmithA.H., GrinwichK.: Subversion of immune system by tumor cells and role of prostaglandines.Proc. Nat. Acad. Sci.72: 1848, 1975.
6.
RothJ.A., GrimmE.A., GuptaR.K., SugarbakerP.H., AmesR.: Suppression of lymphocyte proliferation and cytotoxic responses by human tumor associated immunoregulatory factors.Immunobiology159: 190, 1981.
7.
SamakR., EdelsteinR., IsraelL.: Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer. Cancer Immun.Immunother.13: 38, 1980.
8.
LiptonA., HarveyH.A., De LongS., AllegraJ., WhiteD., AllegraM., DavidsonE.A.: Glycoprotein and human cancer. I. Circulating levels in cancer serum.Cancer43: 1766, 1979.
9.
IsraelL., EdelsteinR., MannoniP., RadotE., GreenspanE.M.: Plasmapheresis in patients with disseminated cancer: clinical results and correlation with changes in serum protein.Cancer40: 3146, 1977.
10.
IsraelL., EdelsteinR.: In-vitro and in-vivo studies on nonspecific blocking factors of host origin in cancer patients: role of plasma exchange as an immunotherapeutic modality. Israel J.Med. Soc.14: 105, 1978.
11.
IsraelL., EdelsteinR., SamakR.: Repeated plasma exchange in patients with metastatic cancer. In: Contributions to oncology 10. Plasmapheresis in immunology and oncology.BeyerJ.H., BorbergH., FuchsC., NagelG.A. eds. S. Karger Basel, München, Paris, London, New York, Tokyo, Sydney p. 196, 1982.
12.
MickscheM., ColotM., KokoschkeE.M., MoserK., RainerH.: Plasmapheresis in patients with advanced disease: a pilot study.Oncology39: 146, 1982.
13.
NagelG.A., BeyerJ.H., KriegerG., RichnerJ., Schuff-WernerP.: Could lg-preparations be helpful adjuncts in cancer treatment? In: Immunotherapy. A Guide to immunoglobulin prophylaxis and therapy.NydeggerU.E. ed. Academic Press, London, New York, Toronto, Sydney, San Francisco1981, p. 337.
14.
BansalS.C., BansalB.R., ThomasH.L., SiegalP.O., RhoadsJ.E., CooperD.R., TermanD.S., MarkR.: Ex vivo removal of serum IgG in a patient with colon carcinoma. Some biochemical, immunological and histological observations.Cancer42: 1, 1978.
15.
RayP.K., ClarkeL., Mc LaughlinD., AllenP., IdicullaA., MarkR., RhoadsJ.E., BassettJ.G., CooperD.R.: Immunotherapy of cancer: extracorporeal adsorption of plasma blocking factors using nonviable Staphylococcus aureus Cowan I. In: Contributions to oncology 10. Plasmapheresis in immunology and oncology.BeyerJ.H., Borberg, FuchsC., NagelG.A. eds. S. Karger Basel, München, Paris, London, New York, Tokyo, Sydney 198, p. 102.
16.
TermanD.S., YoungJ.B., ShearerW.T., AyusC., LehaneD., MattioliC., EspadaR., HowellJ.F., YamamotoT., ZaleskiH.J., MillerL., FrommerP., FeldmanL., HenryJ.F., TillquistR., CookG., DaskalY.: Preliminary observations of the effect on breast adeno-carcinoma of plasma perfused over immobilized Protein A.N. Engl. J. Med.305: 1195, 1981.
17.
HellströmK.E., HellströmI.: Does perfusion with treated plasma cure cancer? N.Engl. J. Med.305: 1215, 1981.
18.
KorecS., PhillipsT.M., DjenJ.Y., RosenoffS.H., SmithF.P., ScheinP.S.: Complex immunological changes in cancer patients induced by perfusing of plasma over filters containing Staphylococcal protein A (SPA). Proceedings of the 19th Annual Meeting of the American Society of Clinical Oncology 1983, Abstract No. C-200, p. 51.
19.
Mac KintoshF.R., BennettK., SchiffS.A., ShieldsJ.A., HallS.W.: Treatment of advanced malignancy with plasma passed over Staphylococcal protein A (SPA): a phase I study. Proceedings of the 19th Annual Meeting of the American Society of Clinical Oncology 1983, Abstract No. C-209, p. 54.
20.
BeyerJ.H., KriegerG., Schuff-WernerP., KösteringH., NagelG.A.: Möglichkeiten der Plasmapherese-Behandlung bei metastasierenden Malignomen.Internist24: 34, 1983.
21.
KösteringH., BeyerJ.H., KleeM., KastenU., Schuff-WernerP., NagelG.A.: Blood coagulation changes induced by repeated plasmapheresis in 12 normal donors and 15 patients with malignomas. In: Contributions to oncology 10. Plasmapheresis in immunology and oncology.BeyerJ.H., BorbergH., FuchsC., NagelG.A. eds. S. Karger Basel, München, Paris, London, New York, Tokyo, Sydney1982, p. 218.
22.
BenneckeJ.S., QualtiereL.F., NesklimM.C., PearsonG.R.: Purification and biochemical characterization of an inhibitor of DNA synthesis produced by Epstein-Barr-virus-transformed B cell line.J. Immunol.124: 2950, 1980.
